MktsMarkets

Immunovant, Inc.
NASDAQ: IMVTKey statistics
IMVT News
Stories mentioning IMVT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | 159,554 | 114,362 | 131,762 | 127,224 | 113,826 | 114,302 | 115,743 | 94,281 |
| Operating Income (Loss) | ||||||||
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 798.00 | (54.00) | 250.00 | 1,187 | 1,072 | (1,258) | 629.00 | 28.00 |
| Pretax Income | (150,700) | (109,083) | (125,908) | (119,700) | (105,865) | (110,970) | (109,041) | (87,073) |
| Tax Provision | (2,844) | 1,552 | 594.00 | 913.00 | 584.00 | 152.00 | 78.00 | 77.00 |
| Net Income (Loss) | (147,856) | (110,635) | (126,502) | (120,613) | (106,449) | (111,122) | (109,119) | (87,150) |
| Earnings Per Share (Basic) | (0.81) | (0.61) | (0.73) | (0.71) | (0.70) | (0.76) | (0.74) | (0.60) |
| Earnings Per Share (Diluted) | (0.81) | (0.61) | (0.73) | (0.71) | (0.70) | (0.76) | (0.74) | (0.60) |
| Weighted Average Shares Outstanding (Basic) | 182,421 | 181,513 | 173,644 | 170,873 | 151,574 | 146,922 | 146,469 | 146,086 |
| Weighted Average Shares Outstanding (Diluted) | 182,421 | 181,513 | 173,644 | 170,873 | 151,574 | 146,922 | 146,469 | 146,086 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About IMVT
Immunovant, Inc. (NASDAQ: IMVT) is a stock listed on the Nasdaq Stock Market under the ticker symbol IMVT. It last traded at $28.59 (Oct 20, 2026, 4:00 PM ET), up 3.5% on the day. That gives Immunovant a market capitalisation of $5.9B.
Over the past 52 weeks IMVT has traded between $17.02 and $45.42.
For the quarter ended Mar 31, 2026 it reported a net loss of $147.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$147.9M |
| Dec 31, 2025 | — | -$110.6M |
| Sep 30, 2025 | — | -$126.5M |
| Jun 30, 2025 | — | -$120.6M |
From Immunovant’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…